

In re: Proud et al.
International Application No.: PCT/GB00/2414
International Filing Date: June 21, 2000
Page 2 of 4

12. (New) A method according to claim 11 wherein said peptide comprises the sequence:

KKRYDREFLLG,
RVRYSQQLLDL, or
RIIYDRKL (L/M).

13. (New) A method according to claim 11 wherein said peptide is 7-25 amino acids in length.

14. (New) A method according to claim 11 wherein said method induces cell death in tumour cells.

15. (New) A method of inducing cell death, said method comprising administering to a recipient a polynucleotide fragment encoding a peptide comprising the sequence:

(K/R) xxYxxx (F/Q) L (L/M)
wherein x is a variable amino acid.

16. (New) A method of inducing programmed cell death, said method comprising administering to a recipient a peptide of 7-25 amino acids in length comprising the sequence:

(K/R) xxYxxx (F/Q) L (L/M)
wherein x is a variable amino acid.

17. (New) A method of inducing programmed cell death in tumour cells, said method comprising administering to a recipient a peptide comprising the sequence:

(K/R) xxYxxx (F/Q) L (L/M)
wherein x is a variable amino acid.

In re: Proud et al.
International Application No.: PCT/GB00/2414
International Filing Date: June 21, 2000
Page 3 of 4

18. (New) A method of inducing programmed cell death in tumour cells, said method comprising administering to a recipient a peptide of 7-25 amino acids in length comprising the sequence:

(K/R) xxYxxx (F/Q) L (L/M)

wherein x is a variable amino acid.

19. (New) A pharmaceutical formulation comprising a peptide comprising the sequence:

(K/R) xxYxxx (F/Q) L (L/M)

wherein x is a variable amino acid, and a pharmaceutically acceptable carrier.

20. (New) A pharmaceutical formulation according to claim 19 wherein said peptide comprises the sequence:

KKRYDREFLLGF,

RVRYSDQLLDL, or

RIIYDRKL (L/M).

21. (New) A pharmaceutical formulation according to claim 19 wherein said peptide is 7-25 amino acids in length.

22. (New) A pharmaceutical formulation comprising a peptide of 7-25 amino acids in length comprising the sequence:

(K/R) xxYxxx (F/Q) L (L/M)

wherein x is a variable amino acid, and a pharmaceutically acceptable carrier.